# Phase II Study of Doxorubicin and Avastin® in Sarcoma.

> **NCT00755261** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 4 (actual)

## Conditions studied

- Sarcoma
- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Avastin
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT00755261
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2010-09
- **Final completion:** 2010-11
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The study has been terminated due to low accrual.
- **Last updated:** 2015-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00755261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00755261, "Phase II Study of Doxorubicin and Avastin® in Sarcoma.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00755261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*